Individuals with chronic hepatitis B virus (HBV) infection or past exposure to HBV infection have a substantial risk of reactivation during immunosuppressive cancer therapy. HBV reactivation can lead to liver failure, cancer treatment interruption or death.
Clinical concordance with screening and treatment guidelines is inconsistent in practice, and existing international guidelines are not specific to the Australian context. An expert panel of infectious diseases, hepatology, haematology and oncology specialists, with representatives from ASHM, the Australasian Society for Infectious Diseases (ASID), The Gastroenterological Society of Australia and the Medical Oncology Group of Australia, have developed an Australian consensus statement to inform hepatitis B screening and antiviral management for immunocompromised patients with haematological and solid organ malignancies in Australia.
See more in the Medical Journal of Australia (subscription) here or access the Consensus Statement here.